Guardant Health (GH)

• Market cap: $5.3B
• 1 day: -9.56%
• 5 days: -9.75%
• 1 month: -5.01%
• 3 months: 38.38%
• 6 months: 51.70%
• Year to date: 34.94%
• 1 year: 89.19%
• 5 years: -51.73%
• 10 years: 33.14%
• Sector: Healthcare
• Industry: Medical Laboratories

About: Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Employees: 1,779

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

100% more first-time investments, than exits

New positions opened: 62 | Existing positions closed: 31

50% more funds holding in top 10

Funds holding in top 10: 4 [Q3] → 6 (+2) [Q4]

29% more capital invested

Capital invested by funds: $2.84B [Q3] → $3.65B (+$810M) [Q4]

9% more funds holding

Funds holding: 266 [Q3] → 290 (+24) [Q4]

8% more repeat investments, than reductions

Existing positions increased: 93 | Existing positions reduced: 86

6.12% less ownership

Funds ownership: 102.8% [Q3] → 96.68% (-6.12%) [Q4]

50% less call options, than puts

Call options by funds: $28.1M | Put options by funds: $56.8M

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $53 24% upside
• Avg. target: $57 32% upside
• High target: $60 40% upside

5 analyst ratings

• positive: 5 100%
• neutral: 0 0%
• negative: 0 0%

Goldman Sachs Matthew Sykes 56% 1-year accuracy 22 / 39 met price target	31% upside $56	Buy Maintained	21 Feb 2025
Raymond James Andrew Cooper 14% 1-year accuracy 2 / 14 met price target	38% upside $59	Outperform Reiterated	21 Feb 2025
JP Morgan Rachel Vatnsdal 65% 1-year accuracy 11 / 17 met price target	28% upside $55	Overweight Maintained	21 Feb 2025
Stifel Daniel Arias 37% 1-year accuracy 7 / 19 met price target	24% upside $53	Buy Maintained	21 Feb 2025
Barclays Luke Sergott 31% 1-year accuracy 16 / 52 met price target	40% upside $60	Overweight Initiated	23 Jan 2025